EUS-B for suspected left adrenal metastasis in lung cancer

Christiansen, Ida Skovgaard; Ahmad, Khaliq; Bodtger, Uffe; Naur, Therese Maria Henriette; Sidhu, Jatinder Singh; Nessar, Rafi; Salih, Goran Nadir; Høegholm, Asbjørn; Annema, Jouke Tabe; Clementsen, Paul Frost

Published in:
Journal of Thoracic Disease

DOI:
10.21037/jtd.2020.01.43

Publication date:
2020

Document version:
Final published version

Document license:
CC BY-NC-ND

Citation for published version (APA):

Go to publication entry in University of Southern Denmark's Research Portal

Terms of use
This work is brought to you by the University of Southern Denmark. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

• You may download this work for personal use only.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk
Introduction

Lung cancer is the most commonly diagnosed cancer and the most frequent cause of cancer death and unfortunately, the prognosis is poor (1). Most cases are non-small cell lung cancer (NSCLC). Accurate staging of NSCLC is crucial for allocation to surgical treatment, which is curative only in cases of localized disease. The recommended treatment of
disseminated NSCLC and of small cell lung cancer involves chemotherapy and radiation therapy. Staging is based on three components: T (the extent of the primary tumor), N (involvement of lymph nodes), and M (distant metastases). The clinical stage (cTNM) is determined before initiation of treatment and is based on any available information for example computed tomography (CT) and positron emission tomography-CT (PET-CT).

The M component is subdivided into intrathoracic dissemination (M1a), a single extrathoracic metastasis (M1b), and multiple metastases (M1c) (2). The adrenal glands are common sites of lung cancer metastasis. Adrenal masses are found in up to 4–7% of patients with potentially resectable lung cancer (3). Approximately two thirds of these masses are benign adenomas (4). Therefore, pathological verification of a suspicious adrenal gland is mandatory for correct TNM classification and for correct treatment of the patient. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and esophageal ultrasound-guided fine needle aspiration (EUS-FNA) have high accuracy for demonstrating lung cancer and lymph node metastases (5,6). Furthermore, several studies have reported the efficacy of EUS-FNA for the detection of metastases in the left adrenal gland (LAG) in patients with lung cancer (7-13). The European Guidelines recommend endosonography for tissue verification from LAG lesions suspected of metastases (5).

EUS-FNA can be performed either with the use of a conventional gastrointestinal ultrasound scope (EUS) or by using the EBUS-scope in the esophagus (EUS-B) (5). EUS-FNA is known to be able to provide tissue samples of lesions below the diaphragm including the LAG (12). EUS-B-FNA has been shown to have equal diagnostic properties to EUS-FNA in diagnosing LAG lesions (13). However, EUS-B-FNA is a relatively novel technique. Therefore, the literature gives us limited access to experience. On this background we want to describe the largest cohort ever reported of patients with suspected lung cancer having the LAG biopsied by EUS-B-FNA for suspected or proven lung cancer between January 1st, 2015 and December 31st, 2017.

EUS-B-FNA sampling of the LAG was performed if a suspicious lesion was present, indicated by either increased metabolic activity at PET, or abnormal appearance at CT or EUS-B (if the LAG appeared enlarged, with loss of seagull sign or in any other way abnormal). Cytological results of the samples were registered and tissue samples were considered adequate when adrenal cells or malignant cells were demonstrated in the sample.

For adequate samples with non-malignant diagnoses at cytopathological evaluation, the results of the biopsies were considered true-negative by at least 6 months follow up (clinical course and/or CT) both for patients with and without lung cancer if clinically relevant.

Sensitivity of malignancy was defined as the number of samples in which EUS-B-FNA provided a diagnosis of any malignancy relative to the total number of targeted lesions that turned out to be malignant (14). By “worst-case” scenario, we understand a scenario were all patients with inconclusive samples or no follow-up are suffering from malignant disease.

By “best-case” scenario, we understand a scenario were only patients with biopsy-proven malignancy are suffering from malignant disease.

Diagnostic yield was defined as the number of samples in which EUS-B-FNA provided a specific diagnosis (malignant or non-malignant) relative to the total number of samples performed with EUS-B-FNA (14).

Data were non-parametric and presented with median and range. Data were processed using SPSS. (IBM SPSS Statistics, version 25. Chicago, IL, USA).

The EUS-B procedure

EUS-B was performed as a part of the endoscopic work up combined with EBUS-TBNA according to the European guideline (5). Initially a bronchoscopy and an EBUS procedure according to a structured protocol as described by Konge et al. (11,15) were performed with the patient in a supine position under conscious sedation. Either a nasal or oral approach was used. Thereafter the EBUS endoscope was retracted from the trachea to a level just above the vocal cords and from this position turned slightly to the left and the back of the patient and advanced into the esophagus under gentle pressure while the patient was encouraged to swallow. Continuous ultrasound imaging was performed and the endoscope was advanced very carefully without pressure to a level below the diaphragm. Five milliliter 4%
Lidocaine was applied to the pharynx and larynx prior to the EUS-B procedure. A structured protocol was followed using an EUS assessment tool (EUS-AT) (11,15,16) with six landmarks identified in this order: the liver, the abdominal aorta, the LAG, lymph node station 7, station 4L and 4R. When an abnormal LAG was demonstrated, a biopsy was taken by introducing the needle through the biopsy channel of the endoscope. Power Doppler was used to prevent puncture of vessels. The tip of the needle was placed in the lesion under real-time ultrasonic guidance and the stylet was then removed. Suction was applied with a syringe and the needle was moved back and forth inside the lesion. At least two samples were taken and the aspirates were processed for both cytological smears and cell block analysis. EUS-B was performed with a flexible ultrasound bronchoscope (Olympus BF-UC180F or UC 180F, Olympus Medical Systems Europe, Ltd., Hamburg) in combination with a Hitachi ultrasound scanner (EUB 6500 or Hivision Preirus, model EZU-MT28-SI) with a linear scanning transducer. A 19 G, a 22 G or a 25 G needle was used for the aspirations (ViziShot Flex 19 Gauge, 22 Gauge Olympus ViziShot and ViziShot 2. Olympus Medical Systems Europe, Ltd., Hamburg, Germany).

**Ethics**

The study was a retrospective observational study without experimental procedures. The study does not fall under the jurisdiction of the scientific ethics system. The study was approved by the Danish Data Protection Agency.

**Results**

A total of 135 patients with the LAG sampled with EUS-B-FNA were identified in our systematic search. Demographic data and final diagnosis of work-up are shown in **Table 1**.

At final diagnosis, 116 patients had a diagnosis of a malignant disease, mostly lung cancer. Of the 19 patients with non-malignant diagnoses after complete work up, at least 6 months follow up without subsequent finding of malignant disease was performed in all patients (10 followed with clinical course, 9 with clinical course and CT). No severe adverse events were recorded for any patients.

A total of 87% (117/135) of the samples were adequate (i.e., containing adrenal cells or malignant cells) at cytopathological evaluation (**Table 2**): the prevalence of malignancy in the LAG was 30% (40/135). In 35 of these 40 patients, the malignant lesion was a metastasis from primary pulmonary cancer, in five patients the malignant lesion was a metastasis from an extra thoracic malignancy. No benign, specific diagnoses were made therefore diagnostic yield was 30% (40/135).

Of the remaining 77 patients with a non-malignant cytopathological finding, follow-up for the LAG lesion was not possible in 51 patients as final work-up showed disseminated malignant disease, and the patients were

<table>
<thead>
<tr>
<th>Variables</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients, n</td>
<td>135</td>
</tr>
<tr>
<td>Gender: female</td>
<td>85 (63%)</td>
</tr>
<tr>
<td>Age, median [95% percentile]</td>
<td>69 [50–84]</td>
</tr>
</tbody>
</table>

**Table 1** Demographic data and final diagnosis of patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Final diagnosis after complete work up</td>
<td></td>
</tr>
<tr>
<td>Primary pulmonary cancer</td>
<td>102 (76%)</td>
</tr>
<tr>
<td>NSCLC</td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>62 (46%)</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>17 (13%)</td>
</tr>
<tr>
<td>NSCLC-NOS</td>
<td>10 (7%)</td>
</tr>
<tr>
<td>SCLC</td>
<td>12 (9%)</td>
</tr>
<tr>
<td>Large cell neuroendocrine carcinoma</td>
<td>1 (1%)</td>
</tr>
<tr>
<td>Metastasis from extra pulmonary tumor</td>
<td>10* (7%)</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>4 (3%)</td>
</tr>
<tr>
<td>Non-malignant</td>
<td>19 (14%)</td>
</tr>
</tbody>
</table>

* from colon: 3, upper gastrointestinal tract: 1, pancreas: 1, mammae: 1, uterus: 1; hepatocellular carcinoma: 1, malignant melanoma: 1, origin of primary tumor never found: 1. NSCLC, non-small cell lung cancer; NSCLC-NOS, non-small cell lung cancer not otherwise specified; SCLC, small cell lung cancer.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytopathological results of samples from the left adrenal gland</td>
<td>135</td>
</tr>
<tr>
<td>Adequate samples*</td>
<td>117 (87%)</td>
</tr>
<tr>
<td>Cytopathological diagnosis of adequate samples</td>
<td></td>
</tr>
<tr>
<td>Non-malignant</td>
<td>77 (66%)</td>
</tr>
<tr>
<td>Malignant</td>
<td>40 (34%)</td>
</tr>
</tbody>
</table>

*, tissue samples were considered adequate when adrenal cells or malignant cells were demonstrated in the sample.

**Table 2** EUS-B-FNA results of left adrenal gland sampling (n=135)
offered systemic, oncological treatment.

Follow-up of the LAG lesion was completed in 26 patients without a diagnosis of cancer (clinical course n=13; clinical course and CT: n=13). Thus, in the best-case scenario, the negative predictive value (NPV) in patients without disseminated malignant disease plus 6-months follow-up was 100%. In a worst-case scenario where the 51 patients without follow-up were considered false-negative, the NPV would be 34% (26/77).

Concerning the 18 inadequate samples, one patient had malignancy at re-EUS-B of the LAG, in 11 patients re-sampling was irrelevant due to disseminated malignant disease, and in 6 patients, 6-months follow-up was without a diagnosis of cancer.

Thus, sensitivity of malignancy was 39% in a worst-case scenario [40 malignant/103 (=40 malignant + 63 samples without follow-up)], and 98% in a best-case scenario [40/41 (=40 malignant at initial EUS-B + 1 malignant at re-examination)]. The characteristics of LAG on CT, PET and EUS-B are shown in Table 3. Of the 44 patients with normal metabolic activity of the LAG on PET the lesion proved malignant in a single case.

**Discussion**

The main finding of our study is that EUS-B-guided biopsy from the LAG is a safe and feasible technique when used as a routine in the hands of chest physicians in the diagnosing and staging of patients with lung cancer.

The current cohort of patients is by far the largest (n=135) ever reported, and the malignancy detection rate of EUS-B-FNA was high.

There is growing evidence of the value of EUS-B for mediastinal staging of lung cancer patients. However, we have very limited data concerning the role of EUS-B for staging of patients with lesions below the diaphragm.

The LAG has been shown to be visualized and biopsied with EUS-B (13,17) in smaller cohorts. Crombag et al. found in a retrospective setting 9 cases with tissue biopsy (17) and in a prospective setting tissue biopsy from 44 cases (13). Crombag et al. found that the success rate of EUS-B-FNA of LAG was comparable to conventional EUS-FNA (13). It should be noted that in these and the present study the length of the relatively short EBUS-scope, compared to the EUS-scope, was not a limiting factor. Our data supports, with a large number of LAG samples, the ability of EUS-B to visualize and biopsy this structure.

Calculations of sensitivity and NPV were performed both with these samples calculated as false negative, worst case scenario, (NPV 34%, sensitivity 39%) and in a best-case scenario (NPV 100%, sensitivity 98%). The true estimates must be placed somewhere in between. This weakness of the study is balanced by the strength of being able to demonstrate the value of the biopsies in a large consecutive, unselected cohort of patients in lung cancer work-up.

The sample adequacy of 87% is in line with earlier findings for EUS-B-FNA as Crombag et al. (13) found a sensitivity of 86% for LAG lesions.

The EUS endoscope traditionally used by the gastroenterologist is excellent for the left and lower paraesophageal structures and structures below the diaphragm such as the LAG, whereas the EBUS endoscope provides access to structures close to the large airways (5,9-11). It is known that EUS-B-FNA with the EBUS endoscope in the esophagus is useful as a supplement to an endobronchial approach for additional sampling of mediastinal nodes

---

**Table 3** Characteristics of left adrenal gland at CT, PET and EUS-B

<table>
<thead>
<tr>
<th>Variables</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of samples</td>
<td>135</td>
</tr>
<tr>
<td>CT performed, n</td>
<td>135</td>
</tr>
<tr>
<td>LAG suspicious at CT*</td>
<td>114 (84.4%)</td>
</tr>
<tr>
<td>LAG not suspicious at CT</td>
<td>21 (15.6%)</td>
</tr>
<tr>
<td>Samples with PET performed, n</td>
<td>74</td>
</tr>
<tr>
<td>LAG suspicious at PET**</td>
<td>30 (40.5%)</td>
</tr>
<tr>
<td>LAG not suspicious at PET</td>
<td>44 (59.5%)</td>
</tr>
<tr>
<td>LAG in EUS-B description, n</td>
<td>110</td>
</tr>
<tr>
<td>LAG described suspicious on EUS-B</td>
<td>91 (82.7%)</td>
</tr>
<tr>
<td>LAG not suspicious on EUS-B</td>
<td>19 (17.3%)</td>
</tr>
</tbody>
</table>

*, CT and EUS-B suspicious when abnormal appearance (left adrenal gland enlarged, loss of seagull sign or in any other way abnormal); **, PET suspicious when increased metabolic activity.
LAG, left adrenal gland.
and the technique has also been shown to give access to tissue samples from intrapulmonary tumors (22).

There are several technical advantages in the use of a conventional EUS-endoscope compared to EBUS-endoscope for the esophageal approach, e.g. better stability in the stomach and the larger ultrasound device. The barriers of use of the EUS-endoscope in lung cancer work-up are that most pulmonologists are not trained using the EUS-endoscope and that it requires another investment in the department already performing EBUS. Of these reasons, EUS-B-FNA is quickly gaining ground in Europe. Currently, one single endoscope that combines the features of the EUS scope mentioned with the EBUS scope designed for both esophagus and trachea does not exist.

Though inclusion in this study was consecutive, a limitation is a selection bias due to the retrospective design. Subsequent studies should include larger cohorts in a prospective multi-centre design including exclusively consecutive patients including prevalence of missed EUS-B-FNA procedures due to inability to reach, visualize and/or sample the LAG.

Our results underline that EUS-B enables the pulmonologist to biopsy lesions in the LAG and thus EUS-B provides tissue proof of potential M1 lesions below the diaphragm.

In the future, interventionul pulmonologists should be trained in both EBUS-TBNA (15) and EUS-B-FNA as recommended in the guidelines (5). Especially EUS-B-guided biopsy from the LAG should be learned.

**Conclusions**

LAG analysis in lung cancer patients can be performed safely with EUS-B-FNA. Therefore, its use should be considered in appropriate lung cancer staging cases. The single EBUS scope approach for both nodal and LAG staging provides obvious logistical and practical advantages.

**Acknowledgments**

**Funding:** None.

**Footnote**

**Conflicts of Interest:** The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was approved by the Danish Data Protection Agency (No. REG-085-2015).

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

**References**


